Citadel Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-800
| Closed | -$1.27K | – | 15851 |
|
|
2024
Q1 | $1.27K | Buy |
800
+700
| +700% | +$1.04K | ﹤0.01% | 14150 |
|
|
2023
Q4 | $86 | Sell |
100
-300
| -75% | -$263 | ﹤0.01% | 14139 |
|
|
2023
Q3 | $428 | Sell |
400
-2,000
| -83% | -$4.14K | ﹤0.01% | 14058 |
|
|
2023
Q2 | $6.22K | Buy |
2,400
+2,100
| +700% | +$7.49K | ﹤0.01% | 13442 |
|
|
2023
Q1 | $1.22K | Sell |
300
-87,800
| -100% | -$406K | ﹤0.01% | 14339 |
|
|
2022
Q4 | $442K | Sell |
88,100
-15,200
| -15% | -$95.3K | ﹤0.01% | 8505 |
|
|
2022
Q3 | $1.35M | Buy |
103,300
+26,600
| +35% | +$403K | ﹤0.01% | 6363 |
|
|
2022
Q2 | $983K | Buy |
+76,700
| New | +$1.06M | ﹤0.01% | 7057 |
|
|
2022
Q1 | – | Sell |
-26,700
| Closed | -$473K | – | 14859 |
|
|
2021
Q4 | $473K | Sell |
26,700
-24,900
| -48% | -$478K | ﹤0.01% | 9840 |
|
|
2021
Q3 | $1.08M | Buy |
51,600
+41,200
| +396% | +$907K | ﹤0.01% | 7939 |
|
|
2021
Q2 | $205K | Buy |
10,400
+3,200
| +44% | +$74.9K | ﹤0.01% | 12110 |
|
|
2021
Q1 | $209K | Sell |
7,200
-2,800
| -28% | -$78.4K | ﹤0.01% | 11608 |
|
|
2020
Q4 | $303K | Sell |
10,000
-3,200
| -24% | -$70K | ﹤0.01% | 9061 |
|
|
2020
Q3 | $210K | Buy |
+13,200
| New | +$241K | ﹤0.01% | 8728 |
|
Citadel Advisors's NGM Position: Q2 2024 in Review
Citadel Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 342,195 shares — an estimated $544K sold.
Citadel Advisors first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $15.9M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Citadel Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 342,195 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $544K.
- Citadel Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Citadel Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $15.9M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.